E&G Advisors’s Novartis NVS Stock Holding History

E&G Advisors’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$791K	Sell	5,177 -104	-2%	-$15.9K	0.18%	100
2025 Q4	$728K	Sell	5,281 -100	-2%	-$13.1K	0.16%	104
2025 Q3	$690K	Buy	5,381 +4	+0.1%	+$488	0.16%	111
2025 Q2	$651K	Sell	5,377 -161	-3%	-$18.1K	0.17%	114
2025 Q1	$617K	Sell	5,538 -100	-2%	-$10.6K	0.17%	115
2024 Q4	$549K	Hold	5,638	–	–	0.15%	119
2024 Q3	$648K	Hold	5,638	–	–	0.18%	110
2024 Q2	$600K	Sell	5,638 -56	-1%	-$5.62K	0.18%	108
2024 Q1	$551K	Sell	5,694 -60	-1%	-$6.15K	0.17%	111
2023 Q4	$581K	Sell	5,754 -644	-10%	-$62.2K	0.21%	99
2023 Q3	$652K	Hold	6,398	–	–	0.24%	91
2023 Q2	$646K	Buy	6,398 +100	+2%	+$10K	0.23%	92
2023 Q1	$579K	Hold	6,298	–	–	0.21%	101
2022 Q4	$571K	Hold	6,298	–	–	0.21%	106
2022 Q3	$479K	Hold	6,298	–	–	0.18%	114
2022 Q2	$532K	Hold	6,298	–	–	0.18%	115
2022 Q1	$553K	Hold	6,298	–	–	0.15%	120
2021 Q4	$551K	Hold	6,298	–	–	0.14%	124
2021 Q3	$515K	Buy	+6,298	New	+$567K	0.14%	127
2021 Q2	–	Sell	-6,298	Closed	-$561K	–	121
2021 Q1	$538K	Hold	6,298	–	–	0.16%	118
2020 Q4	$595K	Hold	6,298	–	–	0.18%	100
2020 Q3	$548K	Buy	6,298 +30	+0.5%	+$2.6K	0.19%	97
2020 Q2	$547K	Hold	6,268	–	–	0.21%	90
2020 Q1	$517K	Sell	6,268 -500	-7%	-$44.6K	0.26%	78
2019 Q4	$641K	Hold	6,768	–	–	0.24%	97
2019 Q3	$588K	Sell	6,768 -150	-2%	-$13.5K	0.24%	101
2019 Q2	$632K	Sell	6,918 -802	-10%	-$67.9K	0.27%	91
2019 Q1	$665K	Buy	7,720 +5	+0.1%	+$401	0.29%	89
2018 Q4	$593K	Sell	7,715 -1,004	-12%	-$78.2K	0.27%	103
2018 Q3	$673K	Sell	8,719 -1,164	-12%	-$86K	0.26%	104
2018 Q2	$669K	Buy	9,883 +6	+0.1%	+$414	0.28%	93
2018 Q1	$716K	Hold	9,877	–	–	0.31%	77
2017 Q4	$743K	Buy	9,877 +1,451	+17%	+$109K	0.31%	70
2017 Q3	$648K	Sell	8,426 -3,125	-27%	-$236K	0.29%	73
2017 Q2	$864K	Hold	11,551	–	–	0.42%	54
2017 Q1	$769K	Buy	11,551 +2,456	+27%	+$164K	0.39%	59
2016 Q4	$594K	Hold	9,095	–	–	0.35%	68
2016 Q3	$644K	Sell	9,095 -8,091	-47%	-$590K	0.38%	65
2016 Q2	$1.27M	Hold	17,186	–	–	0.77%	29
2016 Q1	$1.12M	Sell	17,186 -1,284	-7%	-$87.4K	0.73%	36
2015 Q4	$1.42M	Hold	18,470	–	–	0.85%	31
2015 Q3	$1.52M	Hold	18,470	–	–	0.97%	28
2015 Q2	$1.63M	Buy	18,470 +335	+2%	+$30.7K	0.95%	30
2015 Q1	$1.6M	Sell	18,135 -1,507	-8%	-$134K	0.95%	29
2014 Q4	$1.63M	Sell	19,642 -1,674	-8%	-$139K	1.06%	28
2014 Q3	$1.8M	Hold	21,316	–	–	1.16%	24
2014 Q2	$1.73M	Buy	21,316 +1,898	+10%	+$149K	1.12%	24
2014 Q1	$1.48M	Sell	19,418 -782	-4%	-$57K	1.17%	27
2013 Q4	$1.46M	Buy	+20,200	New	+$1.4M	1.36%	24

Other funds holding NVS

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

E&G Advisors's NVS Position: Q1 2026 in Review

E&G Advisors reduced its Novartis (NVS) stake by 2% in Q1 2026, selling an estimated $15.9K and leaving 5,177 shares worth $791K. The position accounts for 0.18% of the portfolio, ranked #100.

E&G Advisors first reported a position in NVS in Q4 2013 and has held it in 49 quarters since. The position peaked at $1.8M in Q3 2014. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

E&G Advisors held 5,177 shares of Novartis worth $791K as of Q1 2026.
E&G Advisors sold 104 Novartis shares in Q1 2026, an estimated $15.9K.
Novartis made up 0.18% of E&G Advisors's portfolio in Q1 2026, its #100 holding.
E&G Advisors first reported a position in Novartis in Q4 2013 and has held it in 49 quarters since.
E&G Advisors's Novartis position peaked at $1.8M in Q3 2014.
1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on E&G Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.